Anca M Cimpean

Summary

Publications

  1. Raica M, Jitariu A, Cimpean A. Lymphangiogenesis and Anti-lymphangiogenesis in Cutaneous Melanoma. Anticancer Res. 2016;36:4427-35 pubmed
    ..Currently, there are no anti-lymphangiogenic drugs approved for clinical trials. On the other hand, inhibition of lymph node metastasis has been demonstrated in experimental models by inhibiting tumor-associated lymphangiogenesis. ..
  2. Ceausu A, Ciolofan A, Cimpean A, Magheti A, Mederle O, Raica M. The Mesenchymal-Epithelial and Epithelial-Mesenchymal Cellular Plasticity of Liver Metastases with Digestive Origin. Anticancer Res. 2018;38:811-816 pubmed
    ..A MET-targeting strategy, in conjunction with conventional chemotherapy, may be useful for the treatment of liver metastases. ..
  3. Cimpean A, Cobec I, Ceauşu R, Popescu R, Tudor A, Raica M. Platelet Derived Growth Factor BB: A "Must-have" Therapeutic Target "Redivivus" in Ovarian Cancer. Cancer Genomics Proteomics. 2016;13:511-517 pubmed
    ..More than 65% of cases had PDGF-BB mRNA amplification, confirming immunohistochemical results. We herein validated PDGF-BB as a potential therapeutic and prognostic tool of ovarian cancer aggressiveness. ..
  4. Cobec I, Sas I, Pirtea L, Cimpean A, Moatar A, Ceauşu R, et al. Podoplanin as Key Player of Tumor Progression and Lymph Vessel Proliferation in Ovarian Cancer. Anticancer Res. 2016;36:5265-5272 pubmed
    ..Our data support podoplanin as a potential target that may help reduce ovarian cancer dissemination and lymphatic metastasis. ..
  5. Ferician O, Cimpean A, Avram S, Raica M. Endostatin Effects on Tumor Cells and Vascular Network of Human Renal Cell Carcinoma Implanted on Chick Embryo Chorioallantoic Membrane. Anticancer Res. 2015;35:6521-8 pubmed
    ..Interplay between VEGF, endoglin and endostatin in RCC could support a combined targeted therapy to improve prognosis of patients with RCC and reduce therapy resistance often developed by monotherapy. ..
  6. Vladau M, Cimpean A, Balica R, Jitariu A, Popovici R, Raica M. VEGF/VEGFR2 Axis in Periodontal Disease Progression and Angiogenesis: Basic Approach for a New Therapeutic Strategy. In Vivo. 2016;30:53-60 pubmed
    ..Our results support the use of anti-VEGF/VEGFR2-targeted therapy as adjuvant treatment for severe periodontal lesions. ..
  7. Cumpanas A, Cimpean A, Ferician O, Ceauşu R, Sârb S, Barbos V, et al. The Involvement of PDGF-B/PDGFR? Axis in the Resistance to Antiangiogenic and Antivascular Therapy in Renal Cancer. Anticancer Res. 2016;36:2291-5 pubmed
    ..The simultaneous action of PDGF-B/PDGFR? and VEGF165b on the same type of receptor may explain the resistance to antiangiogenic therapy, which depends on the degree of modulation of PDGFR? phosphorylation. ..
  8. Ferician O, Cimpean A, Ceausu A, Dema A, Raica M, Cumpanas A. Heterogeneous vascular patterns in renal cell carcinomas. Pol J Pathol. 2016;67:46-53 pubmed
    ..A complete morphological and molecular characterization of tumor vessels would be beneficial in elucidating the mechanisms that underlie the ineffectiveness of antiangiogenic/antitumor therapies. ..
  9. Cimpean A, Raica M. The Hidden Side of Disodium Cromolyn: from Mast Cell Stabilizer to an Angiogenic Factor and Antitumor Agent. Arch Immunol Ther Exp (Warsz). 2016;64:515-522 pubmed
    ..The expression of growth factors is differentially influenced by sodium cromolyn treatment. ..
  10. Iurciuc S, Avram C, Turi V, Militaru A, Avram A, Cimpean A, et al. Physical Training, Hemodynamic Parameters and Arterial Stiffness: Friends or Foes of the Hypertensive Patient?. In Vivo. 2016;30:521-8 pubmed
    ..6 mmHg (p=0.009) versus 1.6 mmHg (p=0.064), and ?PPao was -6.8 mmHg (p<0.001) versus 3.2 mmHg, (p=0.029) in group A versus B, respectively. Exercise training improves SBP, PP, SBPao, PPao and may delay arterial ageing. ..

Locale

Detail Information

Publications18

  1. Raica M, Jitariu A, Cimpean A. Lymphangiogenesis and Anti-lymphangiogenesis in Cutaneous Melanoma. Anticancer Res. 2016;36:4427-35 pubmed
    ..Currently, there are no anti-lymphangiogenic drugs approved for clinical trials. On the other hand, inhibition of lymph node metastasis has been demonstrated in experimental models by inhibiting tumor-associated lymphangiogenesis. ..
  2. Ceausu A, Ciolofan A, Cimpean A, Magheti A, Mederle O, Raica M. The Mesenchymal-Epithelial and Epithelial-Mesenchymal Cellular Plasticity of Liver Metastases with Digestive Origin. Anticancer Res. 2018;38:811-816 pubmed
    ..A MET-targeting strategy, in conjunction with conventional chemotherapy, may be useful for the treatment of liver metastases. ..
  3. Cimpean A, Cobec I, Ceauşu R, Popescu R, Tudor A, Raica M. Platelet Derived Growth Factor BB: A "Must-have" Therapeutic Target "Redivivus" in Ovarian Cancer. Cancer Genomics Proteomics. 2016;13:511-517 pubmed
    ..More than 65% of cases had PDGF-BB mRNA amplification, confirming immunohistochemical results. We herein validated PDGF-BB as a potential therapeutic and prognostic tool of ovarian cancer aggressiveness. ..
  4. Cobec I, Sas I, Pirtea L, Cimpean A, Moatar A, Ceauşu R, et al. Podoplanin as Key Player of Tumor Progression and Lymph Vessel Proliferation in Ovarian Cancer. Anticancer Res. 2016;36:5265-5272 pubmed
    ..Our data support podoplanin as a potential target that may help reduce ovarian cancer dissemination and lymphatic metastasis. ..
  5. Ferician O, Cimpean A, Avram S, Raica M. Endostatin Effects on Tumor Cells and Vascular Network of Human Renal Cell Carcinoma Implanted on Chick Embryo Chorioallantoic Membrane. Anticancer Res. 2015;35:6521-8 pubmed
    ..Interplay between VEGF, endoglin and endostatin in RCC could support a combined targeted therapy to improve prognosis of patients with RCC and reduce therapy resistance often developed by monotherapy. ..
  6. Vladau M, Cimpean A, Balica R, Jitariu A, Popovici R, Raica M. VEGF/VEGFR2 Axis in Periodontal Disease Progression and Angiogenesis: Basic Approach for a New Therapeutic Strategy. In Vivo. 2016;30:53-60 pubmed
    ..Our results support the use of anti-VEGF/VEGFR2-targeted therapy as adjuvant treatment for severe periodontal lesions. ..
  7. Cumpanas A, Cimpean A, Ferician O, Ceauşu R, Sârb S, Barbos V, et al. The Involvement of PDGF-B/PDGFR? Axis in the Resistance to Antiangiogenic and Antivascular Therapy in Renal Cancer. Anticancer Res. 2016;36:2291-5 pubmed
    ..The simultaneous action of PDGF-B/PDGFR? and VEGF165b on the same type of receptor may explain the resistance to antiangiogenic therapy, which depends on the degree of modulation of PDGFR? phosphorylation. ..
  8. Ferician O, Cimpean A, Ceausu A, Dema A, Raica M, Cumpanas A. Heterogeneous vascular patterns in renal cell carcinomas. Pol J Pathol. 2016;67:46-53 pubmed
    ..A complete morphological and molecular characterization of tumor vessels would be beneficial in elucidating the mechanisms that underlie the ineffectiveness of antiangiogenic/antitumor therapies. ..
  9. Cimpean A, Raica M. The Hidden Side of Disodium Cromolyn: from Mast Cell Stabilizer to an Angiogenic Factor and Antitumor Agent. Arch Immunol Ther Exp (Warsz). 2016;64:515-522 pubmed
    ..The expression of growth factors is differentially influenced by sodium cromolyn treatment. ..
  10. Iurciuc S, Avram C, Turi V, Militaru A, Avram A, Cimpean A, et al. Physical Training, Hemodynamic Parameters and Arterial Stiffness: Friends or Foes of the Hypertensive Patient?. In Vivo. 2016;30:521-8 pubmed
    ..6 mmHg (p=0.009) versus 1.6 mmHg (p=0.064), and ?PPao was -6.8 mmHg (p<0.001) versus 3.2 mmHg, (p=0.029) in group A versus B, respectively. Exercise training improves SBP, PP, SBPao, PPao and may delay arterial ageing. ..
  11. Cimpean A, Balica R, Doros I, Balica N, Gaje P, Popovici R, et al. Epidermal Growth Factor Receptor (EGFR) and Keratin 5 (K5): Versatile Keyplayers Defining Prognostic and Therapeutic Sub-classes of Head and Neck Squamous Cell Carcinomas. Cancer Genomics Proteomics. 2016;13:75-81 pubmed
    ..We herein defined two distinct HNSCCs groups (EGFR(+) and K5(+)) with several sub-classes, identifiable by the additional assessment of p53, Bcl2 and CD117. ..
  12. Comşa S, Popescu R, Avram S, Ceauşu R, Cimpean A, Raica M. Bevacizumab Modulation of the Interaction Between the MCF-7 Cell Line and the Chick Embryo Chorioallantoic Membrane. In Vivo. 2017;31:199-203 pubmed
    ..CAM induces a triple-negative, non-proliferative but still anti-apoptotic status in MCF-7 cells. Although antivasculogenic, bevacizumab stimulates MCF-7 cells to acquire a more aggressive status. ..
  13. Cimpean A, Raica M, Narita D. Diagnostic significance of the immunoexpression of CD34 and smooth muscle cell actin in benign and malignant tumors of the breast. Rom J Morphol Embryol. 2005;46:123-9 pubmed
    ....
  14. Cimpean A, Ceausu A, Corlan A, Melnic E, Jitariu A, Raica M. The "game" of glial fibrillary acidic and S100 proteins in pituitary adenomas: two players or several?. Endokrynol Pol. 2017;68:380-389 pubmed publisher
    ..It is possible that S100+/EGFR+ pituitary adenomas represent a group of pituitary adenomas with an aggressive behaviour and a high ability of invasion and recurrence. ..
  15. Raica M, Cimpean A. Paul Langerhans: a prilgrim "traveling" from functional histology to marine biology. Acta Med Hist Adriat. 2017;15:139-146 pubmed
    ....
  16. Cimpean A, Tarlui V, Cumpanas A, Bolintineanu S, Cumpănaş A, Raica M. Critical Overview of HER2 Assessement in Bladder Cancer: What Is Missing for a Better Therapeutic Approach?. Anticancer Res. 2017;37:4935-4942 pubmed
    ..T3 was correlated with HER2-IHC (p=0.05) and HER2-FISH (p=0.01). Improved HER2 assessement is needed for urothelial carcinomas. HER2-IHC scored as 0-2 should be validated by and reclassified according to FISH analysis. ..
  17. Comşa S, Ceauşu R, Popescu R, Cimpean A, Raica M. The Human Mesenchymal Stem Cells and the Chick Embryo Chorioallantoic Membrane: The Key and the Lock in Revealing Vasculogenesis. In Vivo. 2017;31:1139-1144 pubmed
    ..hMSC and CAM establish a genuine hotspot of vasculogenesis, which may evolve to a valuable experimental model for this research field. ..
  18. Cimpean A, Raica M, Suciu C. CD105/smooth muscle actin double immunostaining discriminate between immature and mature tumor blood vessels. Rom J Morphol Embryol. 2007;48:41-5 pubmed
    ....